Liege (Belgium) - December 23, 2008, 2:00 PM CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) publishes required information in accordance with the Belgian Act on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market (Belgian Act of May 2, 2007).
Further to the capital increase announced on December 16 and completed on December 18, 2008 the basic data as published on September 12, 2008 has changed as follows (status as per December 18, 2008):
Basic data
Total capital: EUR 53,900,693.70
Total number of securities conferring voting rights: 13,161,074 shares
Total number of voting rights (the denominator): 13,161,074 (one voting right per share)
Update on supplementary data:
Supplementary data
Total number of bonds convertible into securities conferring voting rights: zero
Total number of outstanding warrants convertible into securities conferring voting rights: 241,435.
Total number of voting rights that may result from the exercise of outstanding warrants: 421,023
Total number of shares without voting rights: zero
The board of directors has also approved the grant of 120,000 new warrants to employees of the company effective January 2009. Consequently, 120,000 new voting rights may result from the exercise of these new warrants if the warrants are accepted by the beneficiaries and eventually become vested and exercised.
Further information concerning the transparency legislation
Detailed information concerning the transparency legislation can be found in the Extract from the “Guide to the Transparency Legislation CBFA_2008_16 of 8 July 2008" which is available from the website of the Banking, Finance and Insurance Commission (CBFA): www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf
About OncoMethylome Sciences
OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company’s tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient’s response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome Sciences SA boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, and Millipore Corporation’s BioScience Division. OncoMethylome Sciences’ products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome Sciences SA has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
